## A BILL FOR AN ACT

RELATING TO HARM REDUCTION.

#### BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1 SECTION 1. The legislature finds that sharing injection 2 equipment among individuals who use drugs is a major contribution to the spread of human immunodeficiency viruses 3 (HIV), hepatitis B, hepatitis C, and other serious bloodborne 4 5 infections. Act 152, Session Laws of Hawaii 1992, authorized the establishment of the first state-funded sterile needle and 6 syringe exchange program in the United States. The program has 7 aimed to prevent the transmission of bloodborne pathogens and to 8 9 provide individuals who inject drugs with services such as referrals to appropriate health and social services, thereby 10 11 reducing overall disease burden in Hawaii.

Over the past thirty years, extensive scientific research has confirmed that syringe exchange programs nationwide effectively reduce disease transmission, increase access to addiction treatment, improve public safety, lower health care costs, and do not lead to an increase in drug use or crime.
Research has also helped identify the most effective approaches



in what are now commonly referred to as "syringe services
 programs".

3 A 2020 report by the Centers for Disease Control and Prevention, United States Department of Health and Human 4 Services, concluded that syringe programs that restrict syringe 5 6 distribution to one-to-one exchange are less effective than 7 needs-based distribution programs that provide sterile needles 8 and syringes to syringe exchange participants in quantities 9 sufficient to reduce the likelihood of needles and syringes 10 being shared or reused. The Centers for Disease Control and 11 Prevention supports needs-based approaches to syringe 12 distribution based on evidence that it is the best practice for 13 reducing new HIV and viral hepatitis infections. The Centers 14 for Disease Control and Prevention concludes that, compared to one-to-one exchanges, needs-based syringe distribution results 15 in less syringe sharing and reuse, lowers risk of infection, and 16 17 is not associated with increased unsafe syringe disposal. 18 Research shows that syringe distribution programs are safe, 19 effective, cost-saving, do not increase drug use or crime, and do not cause people to begin injecting drugs. However, Hawaii 20 and Florida remain the only states that impose a strict 21

## 2025-1841 SB1433 SD2 SMA.docx

3

one-to-one sterile needle and syringe exchange limit. This Act
 will authorize the State's syringe exchange program to
 transition from a one-to-one exchange model to a needs-based
 distribution system.

5 Syringes and needles are not the only injection equipment 6 that contribute to the spread of infection. Any materials used 7 in the preparation or administration of drugs may potentially 8 transmit pathogens or cause injury when shared or reused.

9 The Model Syringe Services Program Act, a model legislation released by the White House Office of National Drug Control 10 11 Policy in December 2021, recommends extending protection from criminal liability under drug paraphernalia statutes to syringe 12 program staff, volunteers, and participants while implementing 13 14 or accessing program services intended to reduce transmission of bloodborne infections. This Act makes amendments consistent 15 16 with those recommendations.

In alignment with recommendations for improving effectiveness, the State's sterile needle and syringe exchange program also facilitates access to critical health services necessary for participants. These include educating participants about the dangers of contracting HIV through

### 2025-1841 SB1433 SD2 SMA.docx

Page 3

# **S.B. NO.** <sup>1433</sup> S.D. 2

1 sharing drug injection equipment and offering counseling 2 services and referrals for treatment of substance use disorders. 3 Furthermore, individuals who do not inject drugs but are 4 marginalized often seek harm reduction information, supplies, 5 and referrals to other services through the program. This Act 6 will remove the requirement that the program exclude non-7 injection drug users, ensuring the program can assist 8 individuals in need when resources are available.

9 Syringe services programs also play a crucial role in 10 collecting and safely disposing of used injection equipment. 11 Safe disposal occurs most effectively if program participants 12 batch all used injection equipment for safe disposal by syringe 13 services programs. However, participants may be reluctant to 14 batch used injection equipment for safe disposal if they risk 15 criminal penalties for drug residue found on used equipment. 16 Extending protection to program participants from arrest and 17 prosecution for possession of drug residue on used syringes and 18 needles will increase the likelihood of proper disposal, thereby 19 reducing public health risk. Program staff regularly encourage 20 participants to batch and return all used injection equipment to 21 the syringe exchange program, not only for the safety of the



# **S.B. NO.** <sup>1433</sup> S.D. 2

1	community, but also to assist in ensuring the program's
2	continuity. For these reasons, the Model Syringe Services
3	Program Act recommends providing immunity from criminal
4	penalties for possession of a controlled substance or other
5	illicit drug due to the presence of residue in a hypodermic
6	needle or syringe or other supplies.
7	The purpose of this Act is to improve the safety,
8	effectiveness, and cost savings of the State's sterile needle
9	and syringe exchange program by amending it based on current
10	recommendations from the Centers for Disease Control and
11	Prevention and the White House Office of National Drug Control
12	Policy's model legislation.
13	SECTION 2. Section 325-111, Hawaii Revised Statutes, is
14	amended as follows:
15	1. By adding five new definitions to be appropriately
16	inserted and to read as follows:
17	""Authorized objects" means objects authorized by the
18	department for dissemination to syringe exchange participants
19	for the purpose of reducing infection or injury; provided that
20	the objects are incidental to syringe exchange. "Authorized

1	objects" may include, but are not limited to, cookers, cottons,
2	<u>or ties.</u>
3	"Needs-based distribution" means a syringe distribution
4	practice that provides sterile needles and syringes to syringe
5	exchange participants in quantities sufficient to reduce the
6	likelihood of needles and syringes being shared or reused.
7	"Program staff" means an employee of the department or its
8	designee who is specifically tasked with procuring, handling,
9	transporting, and providing sterile needles, syringes, and
10	authorized objects and services to syringe exchange
11	participants.
12	"Residue" means the amount of controlled substance, as that
13	term is defined in section 329-1, remaining in a syringe and
14	needle after the plunger stopper is fully depressed.
15	"Syringe exchange participant" means an injection drug user
16	who receives a sterile needle and syringe pursuant to the
17	program."
18	2. By repealing the definition of "participant".
19	[""Participant"-means-an-injection drug user who exchanges a
20	sterile needle and syringe unit pursuant to the program."]

## S.B. NO. <sup>1433</sup> S.D. 2

SECTION 3. Section 325-113, Hawaii Revised Statutes, is 1 2 amended to read as follows: 3 "[{]\$325-113[]] Operation of the program. (a) The 4 program shall be operated for the purpose of: 5 Preventing the transmission of the human (1)6 immunodeficiency virus, [the] hepatitis B virus, 7 hepatitis C virus, and other [blood borne diseases;] 8 bloodborne infections; and 9 Providing [injection] drug users with referrals to (2) 10 appropriate health and social services. 11 (b) The program shall provide for maximum security of 12 exchange sites and equipment, including a full accounting of the 13 number of needles and syringes  $[in use_r]$  distributed, the number 14 in storage, the number of used needles and syringes collected, 15 and any other measure that may be required to control the use 16 and dispersal of sterile needles and syringes; provided that a 17 syringe exchange participant may exchange used needles and 18 syringes at any exchange site if more than one site is 19 available.

20 (c) The program shall provide [for a one-to-one exchange,
21 whereby the participant shall receive one sterile needle and

## 2025-1841 SB1433 SD2 SMA.docx

S.B. NO.  $^{1433}_{S.D. 2}$ 

1	<del>syringe uni</del>	it in exchange for each used one.] needs-based
2	distributio	on of sterile needles and syringes.
3	(d) ]	The program [ <del>shall provide procedures for the</del>
4	screening (	of participants to prevent non-injection drug users
5	from partic	cipating in the programs.] may provide screening
6	procedures	to allow non-injection drug users to safely and
7	effectively	y receive services, exclusive of syringes and needles,
8	from the pr	rogram.
9	(e) ]	The department and its designees shall keep records to
10	identify ar	nd authorize [ <del>persons employed by the department or</del>
11	<del>its designe</del>	ees] program staff to have access to needles,
12	syringes, c	or authorized objects, and the program's records.
13	(f) 1	The program shall include services to:
14	(1) E	Educate the syringe exchange participant about the
15	C	dangers of contracting [HIV infection] <u>bloodborne</u>
16	Ē	pathogens through [needle-sharing] needle- and other
17	n	naterials-sharing practices; and
18	(2) C	Offer substance [ <del>abuse</del> ] <u>use disorder</u> treatment
19	r	referral and counseling services to all <u>non-injection</u>
20	<u> </u>	drug users and syringe exchange participants.

### S.B. NO. <sup>1433</sup> S.D. 2

1	(g) The program shall compile research data on behavioral
2	changes, enrollment in [ <del>drug abuse</del> ] <u>substance use disorder</u>
3	treatment, counseling, and education programs, service
4	provision, disease transmission, and other information that may
5	be relevant and useful to assist in the planning and evaluation
6	of efforts to combat the spread of [ <del>blood borne diseases.</del> ]
7	bloodborne infections."
8	SECTION 4. Section 325-114, Hawaii Revised Statutes, is
9	amended to read as follows:
10	"[ <del>[</del> ]§325-114[ <del>] Criminal liability.</del> ] Liability. (a)
11	[Exchanges under the sterile needle and syringe exchange
12	program] Possession or delivery of needles or syringes shall not
13	
15	constitute an offense under section 329-43.5 for [ <del>the</del>
13	constitute an offense under section 329-43.5 for [ <del>the</del> <del>participant or for the employees of the department or its</del>
14	participant or for the employees of the department or its
14 15	participant or for the employees of the department or its designees.] program staff acting in the course and scope of
14 15 16	participant or for the employees of the department or its designees.] program staff acting in the course and scope of official duties; provided that delivery is limited to other
14 15 16 17	participant or for the employees of the department or its designees.] program staff acting in the course and scope of official duties; provided that delivery is limited to other program staff or to syringe exchange participants pursuant to



# **S.B. NO.** <sup>1433</sup> S.D. 2

1	(b) Possession or delivery of authorized objects shall not
2	constitute an offense under section 329-43.5 for program staff
3	acting in the course and scope of official duties; provided that
4	delivery is limited to other program staff or to syringe
5	exchange participants pursuant to this part. Possession of
6	authorized objects shall not constitute an offense under section
7	329-43.5 for syringe exchange participants participating in a
8	program visit. The department shall establish a specific list
9	of authorized objects, which may be updated from time to time as
10	needed.
11	(c) Possession or delivery of used needles or syringes
11 12	(c) Possession or delivery of used needles or syringes containing residue shall not constitute a drug possession
12	containing residue shall not constitute a drug possession
12 13	containing residue shall not constitute a drug possession offense under section 712-1242(1)(c), 712-1243, 712-1245(1)(c),
12 13 14	<pre>containing residue shall not constitute a drug possession offense under section 712-1242(1)(c), 712-1243, 712-1245(1)(c), 712-1246.5, 712-1248(d), or 712-1249, for syringe exchange</pre>
12 13 14 15	containing residue shall not constitute a drug possession offense under section 712-1242(1)(c), 712-1243, 712-1245(1)(c), 712-1246.5, 712-1248(d), or 712-1249, for syringe exchange participants within two months after their last participation in
12 13 14 15 16	containing residue shall not constitute a drug possession offense under section 712-1242(1)(c), 712-1243, 712-1245(1)(c), 712-1246.5, 712-1248(d), or 712-1249, for syringe exchange participants within two months after their last participation in a program visit; and shall not constitute an offense for program
12 13 14 15 16 17	containing residue shall not constitute a drug possession offense under section 712-1242(1)(c), 712-1243, 712-1245(1)(c), 712-1246.5, 712-1248(d), or 712-1249, for syringe exchange participants within two months after their last participation in a program visit; and shall not constitute an offense for program staff acting in the course and scope of official duties;

# **S.B. NO.** <sup>1433</sup> S.D. 2

1	(d)	Subsections (a), (b), and (c) shall only apply to
2	needles,	syringes, or authorized objects possessed by syringe
3	exchange	participants or program staff; or to needles, syringes,
4	or_author	ized objects delivered between program staff, or
5	between a	syringe exchange participant and program staff.
6	Subsectio	on (a), (b), or (c) shall not apply to any needles,
7	syringes,	or authorized objects possessed by anyone other than
8	<u>sy</u> ringe e	xchange participants or program staff, nor shall
9	subsectio	n (a), (b), or (c) apply to any needles, syringes, or
10	authorize	d objects delivered between:
11	(1)	Syringe exchange participants;
12	(2)	A syringe exchange participant and an individual who
13		is neither a syringe exchange participant nor program
14		<pre>staff;</pre>
15	(3)	Individuals who are neither syringe exchange
16		participants nor program staff; or
17	(4)	An individual who is neither a syringe exchange
18		participant nor program staff.
19	(e)	A law enforcement officer who, acting in good faith,
20	<u>arrests c</u>	r charges a person who is thereafter determined to be
21	<u>exempt fr</u>	om an offense pursuant to this section shall not be



subject to civil liability for the mere arrest or filing of
 charges.

3 [(b) Nothing] (f) Except as specifically provided in this section, nothing in this part provides immunity from prosecution 4 5 to any person for violation of any law prohibiting or regulating 6 the use, possession, dispensing, distribution, or promotion of 7 controlled substances, dangerous drugs, detrimental drugs, or harmful drugs. [Nothing] Except as specifically provided in 8 9 this section, nothing in this part provides immunity from 10 prosecution to any person for violation of [sections] section 11 329-41, 329-42, or 712-1241 through [712-1249.6.] 712-1249.7." SECTION 5. Section 325-116, Hawaii Revised Statutes, is 12 13 amended to read as follows:

14 "[+]\$325-116[+] Reports. The department, on or before 15 January 1 of each year, shall submit a report to the oversight 16 committee. The report shall include:

17 (1) Information as to the number of <u>syringe exchange</u>
18 participants served [and], the number of needles and
19 syringes distributed[;], and the number of used
20 needles and syringes collected;



# **S.B. NO.** $^{1433}_{S.D. 2}$

1	(2)	A demographic profile of the syringe exchange
2		participants served, including but not limited to:
3		age, sex, ethnicity, area of residence, occupation,
4		types of drugs used, length of drug use, and frequency
5		of injection;
6	(3)	Impact of the program on needle and syringe sharing
7		and other high risk behavior;
8	(4)	Data on <u>syringe exchange</u> participants regarding [ <del>HIV</del> ]
9		human immunodeficiency virus (HIV) testing,
10		counseling, drug treatment, and other social services,
11		including referrals for HIV testing and counseling and
12		for [ <del>drug abuse</del> ] <u>substance use disorder</u> treatment;
13	(5)	Impact on the transmission of HIV infection among
14		injection drug users;
15	(6)	Impact on behaviors that caused syringe exchange
16		participants to be at risk for HIV transmission such
17		as frequency of drug use and needle sharing;
18	(7)	An assessment of the cost-effectiveness of the program
19		versus direct and indirect costs of HIV infection; and
20	(8)	Information on the percentage of persons served
21		through treatment programs for injection drug users



funded through the department that were attributed to 1 needle exchange referrals. 2 3 The report shall address the strengths and weaknesses of 4 the program, the advisability of its continuation, amendments to the law, if appropriate, and other matters that may be helpful 5 to the oversight committee in evaluating the program's 6 7 efficacy." SECTION 6. Statutory material to be repealed is bracketed 8 and stricken. New statutory material is underscored. 9 10 SECTION 7. This Act shall take effect upon its approval.



#### Report Title:

Department of Health; Sterile Needle and Syringe Exchange Program; Needs-Based Distribution; Non-Injection Drug User Participation; Liability

#### Description:

Amends the distribution system of sterile needles and syringes under the Sterile Needle and Syringe Exchange Program from a one-to-one exchange system to a needs-based distribution system. Authorizes non-injection drug user participation in the Program. Modifies liability for Program participants, staff, and law enforcement officers. (SD2)

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

